Objectives: Uncontrolled pain in advanced cancer is a common problem and has significant impact on individuals' quality of life and use of healthcare resources. Interventions to help manage pain at the end of life are available but there is limited economic evidence to support their wider implementation. We conducted a case study economic evaluation of two pain selfmanagement interventions (PainCheck and Tackling Cancer Pain Toolkit (TCPT)) compared to usual care.
Background
Towards the end of life a significant proportion of cancer patients experience severe pain. (1, 2) A European survey of 5,000 cancer patients found that 72% experienced pain, 90% of which was of moderate-to-severe intensity.(2) Inadequate management of pain at the end of life is likely to have a significant detrimental impact on quality of life (3) and may lead to increased healthcare costs through unplanned hospital visits and admissions.(4) Indeed, one study indicated that poor pain control is the most frequent reason that cancer patients at home need emergency medical help.(5) Clearly, achieving good pain management at the end of life is a priority but service provision in this regard often falls short and interventions that are known to be effective are poorly implemented.
There is growing evidence that self-management strategies facilitated by better communication, pain assessment and patient education can lead to improved pain outcomes.(6, 7) However, economic evidence for these types of interventions is less abundant. Despite the acknowledgement that economic evidence is key to improving access to effective palliative care (8, 9) evaluations are still relatively rare in this context (9, 10) and evaluations in the more specific context of pain at the end of life are rarer still. (11) We sought to generate evidence on the cost-effectiveness of pain self-management strategies at the end of life by conducting evaluations of case study interventions. Improving the Management of Pain from Advanced Cancer in the Community (IMPACCT) is a UK research programme aimed at the development and testing of interventions for patients at home to facilitate improved pain outcomes through self-management when delivered in addition to routine community palliative care services. The Tackling Cancer Pain Toolkit (TCPT) is a small booklet and DVD containing information on pain and medicines, alongside self-directed learning activities and sources of further information. PainCheck is an internet based pain monitoring system that enables patients to communicate pain data to health professionals routinely. The system alerts professionals when pain scores are above specific thresholds, and allows them to provde feedback through the system or contact patients directly for further assessment.
Primary research evaluating the effectiveness of the IMPACCT interventions is on-going. The aim of the current research was to conduct economic evaluations of PainCheck and TCPT interventions when added to community palliative care delivery to estimate their value for money compared with usual care. The evaluation adopted a decision-analytic modelling approach incorporating published estimates of effectiveness from similar interventions and was designed to inform implementation strategies.
Methods
The economic evaluation followed the NICE reference case (12) and hence was a cost-utility analysis with the primary outcome cost per incremental quality-adjusted life year (QALY) presented from the perspective of the UK healthcare and personal social services provider.
The evaluation compared the PainCheck and TCPT pain management strategies in cancer patients at the end of life with usual care in this context. We defined usual care as routine care received by the patients at home from their local community palliative care team as determined by local policies and practices. As part of usual care in the UK, patients at the end of life with specialist needs (for example, poorly controlled pain) should be referred to community palliative care specialists and receive pain treatment and advice as part of that care. While this practice is increasing, services are highly variable across the UK and pain is often managed solely via GPs and community pharmacists. There is no set visit routine as patients access services as and when required but those on strong opiates will typically be reviewed 2-3 times per month, depending on response. During these contacts with health care professionals, response is assessed with pain rating items (such as those in the Numeric Pain Rating Scale) and with less formal questions about pain.
Decision model
We developed a decision-analytic model to facilitate the economic evaluation, an earlier version of which has been previously described. 
Health state utility
The utility values for the health states (Table 1) were derived from the IMPACCT patient survey in which respondents completed the EQ-5D-3L measure scored using the UK tariff. (15) We also conducted a sensitivity analysis where utilities were based on the EORTC-8D measure. (16) In view of the fact that the QALY framework has been criticised in palliative care
(17), we conducted another analyses based on the ICECAP measure (18) which adopts the capability framework but which may enable cost-utility analyses.
Transition probabilities

Meta-review of educational and monitoring interventions
We conducted a meta-review of educational and feedback/monitoring interventions for improving cancer pain at the end of life. We searched for randomised controlled trials (RCTs) of non-pharmacological interventions in advanced cancer pain and for reviews in this area. publications were excluded. Two researchers reviewed abstracts and differences were resolved by consensus meeting. The shortlisted publications were discussed with a clinician to identify which best reflected the properties of the IMPACCT interventions and hence were suitable proxy estimates of effectiveness. In particular, we were interested in studies of interventions that encouraged self-management (as opposed to having significant levels of health care professional input). In identifying a suitable review study, we assessed their inclusion criteria to ensure this aligned with the two IMPACCT interventions.
Candidate studies had to report synthesised estimates of effectiveness (and standard error/deviation). Effectiveness had to be based on the Numeric Pain Rating Scale (NPRS) (19) .
The NPRS is a reliable and valid, self-complete measure of pain. Responses are captured on an 11-point numeric scale ranging from '0' (i.e. "no pain") to '10' (i.e. "pain as bad as you can imagine"). NPRS questions cover worst intensity, least intensity and average intensity (over the last 24 hours). Our review specifically attempted to identify reports of average pain intensity as this item was also included in the IMPACCT patient survey and was the basis of health state parameters. We also considered RCTs that were published after reviews had been completed.
Effectiveness, pain progression and survival
The initial distribution between the pain severity groups was determined by the IMPACCT patient survey (Table 1) . Effectiveness translated into health state transition probabilities by observing the pain category change in the IMPACCT survey respondents following the relevant pain reductions. Intervention effects (rather, a sixth of) were assumed to occur on an incremental basis for six weeks after which pain levels were maintained. In the usual care arm pain was assumed to progress over time. Progression was based on a multinomial regression model predicting change in EQ-5D-3L pain/discomfort item response over time and after controlling for survival in a recent trial including cancer patients at the end of life. (20) The survival of the cohort was estimated using parametric regression which was fitted to other IMPACCT data. The data (n=4,638; 84% with a cancer diagnosis) was retrospectively collected on all patient referrals to specialist palliative care services in the city of Leeds, UK over 2 years (2012-2014). The sample had a mean survival of 80.77 days (SD=117.81). A number of models were applied to the data including exponential, Weibull and Gompertz.
Based on best visual fit with the observed Kaplan-Meier curve and lowest Akaike information criterion (AIC) value, Weibull was selected. As the gamma factor was significant the use of the Weibull model is justified as this indicates a non-constant (and declining) hazard function.
The same risk estimates from this analysis were applied to all health states. The survival model estimates were permitted to vary in the probabilistic sensitivity analysis following
Cholesky decomposition for correlated regression parameters. During the 52-week model time horizon, 97% of the cohort were expected to have died. Although there is some evidence that pain can independently explain survival, the evidence is mixed (21) and thus here we assumed they are unrelated. basing QALY calculations on the EORTC-8D and ICE-CAP; and removing the half cycle correction. We conducted additional analyses exploring the impact of using costs from individual studies identified by the systematic reviews. For PainCheck, a U.S. study was used as an alternative source of intervention costs (22) and for TCPT we used a Dutch study (23) ; these were chosen from the review as they had relatively large sample sizes, levels of effectiveness similar to the overall mean and as they reported the resources required to deliver the interventions (see Error! Reference source not found.).
We also conducted threshold analyses to establish the costs and effectiveness required to achieve cost-effectiveness. We conducted a probabilistic sensitivity analysis (PSA) to characterise overall parameter uncertainty in the model by assigning probability distributions to each of the input parameters, and randomly drawing from these probabilities over the 10,000 Monte Carlo simulations, yielding 10,000 estimates of ICERs and INMB. PSA results were plotted on the cost-effectiveness plane and INMB estimates used to generate the costeffectiveness acceptability curve (CEAC) (24) The CEAC illustrates the probability that each intervention would be cost-effective given a range of willingness-to-pay thresholds.
Discounting was not required as all costs and benefits were experienced within one year. A half-cycle correction was applied buta sensitivity analysis was also conducted where no halfcycle correction was applied Finally, we explored the value of further research by conducting a value of information (VoI)
analysis which attaches a formal cost to the uncertainty in the cost-effectiveness results. (25) We estimated population level expected value of perfect information (EVPI) which required information on the number of patients who could benefit from the interventions (incidence and number of years the decision is relevant for 
Results
The PRISMA flow diagram for the literature review is included in supplementary material (Supplementary figure 1) . Seventeen reviews (Supplementary Table 3 ) were identified and discussed with the lead clinician. Reviews were not deemed suitable for a number of reasons including: not synthesising study results (e.g. (6, 28) ); including non-cancer studies (e.g. (29) We tested this value in the model in a comparison with usual care but included the full costs for both active interventions.
The results from the base case and sensitivity analyses are included in Table 2 . PainCheck and TCPT were both cost-saving and more effective than (i.e. they dominated) usual care.
However, TCPT led to greater NMB. In general, the incremental costs and benefits were modest. Sensitivity analyses exploring alternative utility values, costs and maintenance of effect after six weeks in most cases did not change the conclusion for either intervention. Only changes to the levels of effectiveness substantively altered the results. Using the upper confidence interval from the respective meta-analyses led to PainCheck no longer being costeffective while TCPT remained cost-effective. Adopting alternative intervention costs (and effects) from individual studies from within the systematic reviews had the same effect. 
Discussion
These analyses represent the most comprehensive assessment to date of the value for money of pain management interventions at the end of life. Using a decision modelling approach, we compared two types of intervention (educational and pain monitoring/feedback) against usual care from the perspective of the health and social care provider. We relied on estimates of effectiveness from published meta-analyses. PainCheck and TCPT are relatively inexpensive and the evaluations suggest that both have the potential to be cost-effective. Indeed, in the base case analyses, both interventions were cheaper and more effective than usual care. The conclusions were relatively robust to a number of sensitivity analyses. The effectiveness parameter appeared relatively more influential in determining cost-effectiveness than intervention costs or utility values. Assuming all patients were either in moderate or severe pain improved the benefit of the IMPACCT interventions noticeably. A scenario where both interventions were received would be a worse strategy than implementing TCPT alone, mainly due to the additional costs of PainCheck. However, assumptions were made here on the level of combined effect.
Although the use of the generic QALY framework (based on EQ-5D) to evaluate palliative care interventions has been questioned (17) , here the use of condition specific QALY (EORTC-8D) and capability-based approaches (ICE-CAP) yielded reduced incremental benefits for the active interventions. It is possible that the EQ-5D fails to capture additional benefits this patient group may experience following improved pain management such as a greater feeling of control and the emotional positives that come with being able to stay at home. However, the EQ-5D appears adept at discriminating between people based on pain level and this may explain the relative performance of the utility measures as the decision-model is predicated on pain categories.
The probabilistic analyses suggest that both PainCheck and TCPT are highly likely to deliver QALY gains over usual care. However, in both cases, the interventions were less likely to lead 
Limitations
We did not have direct estimates of the effectiveness of either active case study interventions evaluated here and relied on synthesised estimates from meta-analyses. While the studies employed in the analyses as the basis of effectiveness estimates were selected following a meta-review and due consideration, it is possible that these reviews incorporate studies that are not accurate reflections of the PainCheck and TCPT interventions. It is possible that these reviews and synthesised outcomes derive from disparate study interventions or designs which may have biased results. Adam and colleagues (35) , reviewing patient feedback/monitoring studies, found most were prone to some element of bias and that two studies contributing to the synthesis should be treated with caution. As the effectiveness estimates in those two studies were above the mean, their exclusion would reduce the assumed overall effectiveness (albeit slightly given study weightings) for PainCheck. While there were very few reviews relating to patient feedback/monitoring, there were several targeting educational interventions.
The review by Bennett and colleagues was selected based on appropriateness of their study inclusion criteria. There is limited information in the review of the quality of studies included and potential for bias. Examination of study outcomes indicates the presence of significant heterogeneity with one outlier study reporting a very large intervention effect and this may have biased results. However, it is worth pointing out that the uncertainty in outcome should be captured in the probabilistic sensitivity analyses presented here. Furthermore, excluding that study from the weighted mean still yielded an effect greater than that required (-0.40) for
TCPT to be cost-effective. Although, of course, this is based on the use of costs estimated here for the TCPT intervention. It is also possible that there may be individual randomised controlled trials that better reflect the potential effect of either active intervention.
Although it has been suggested that informal care costs are an important consideration in palliative care economic evaluations (38) we did not include these in the current analyses. We wished to adhere to the NICE reference case which excludes these costs but, more importantly, we did not have health state data relating to informal care costs. It is likely that carers of patients in higher pain categories incur higher costs; thus, adopting a broader perspective and including informal care costs would likely increase the estimates of value for money for PainCheck and TCPT. However, increased self-management may also increase informal care requirements and further research is needed to explore this.
Further research and implications
The decision model generated and tested here is robust and may be a tool that, following adaptations, has other useful applications in this palliative care. It may also be useful for local decision makers considering commissioning alternative pain management strategies. The active interventions evaluated here have the potential to be cost-effective and additional research, for example, in the form of randomised trials or observational data collection and analysis, may be warranted to add to the evidence base. usual care;****Weekly probability applied only to standard care arm, all other transition probabilities assumed to be 0.0; *****Weekly mortality following referral to palliative care 
